There was no evidence demonstrating other significant safety issue differences (such as serious adverse events, adjudicated cardiovascular events) between combination therapy and monotherapy
Its proposed mechanisms include modulation of ACTH release, antioxidant activity, and opioid system interaction, but most human evidence is weak or dated
Biochemical and histological analyses were performed on the hippocampal and cortical tissue, assessing oxidative stress markers, antioxidant enzyme activity, and glial activation through spectrophotometric assays and immunohistochemistry
Important Safety Information Do not use AOD-9604 if you: Have a known hypersensitivity to growth hormone fragments or any component of the formulation Have active malignancy (cancer that is currently being treated or monitored) Are pregnant or breastfeeding (insufficient safety data) Have a history of severe allergic reactions to peptide therapies Common side effects (typically mild and transient): Headache, mild gastrointestinal disturbances (flatulence, mild diarrhea at higher doses), upper respiratory tract symptoms, injection site reactions (redness, mild discomfort) Seek medical attention if you experience: Signs of allergic reaction (hives, difficulty breathing, swelling of face or throat), persistent gastrointestinal symptoms, unexplained significant changes in energy, mood, or physical symptoms Clinical Safety Data Safety studies involving approximately 900 participants across six randomized controlled trials documented that AOD-9604 displayed a very good safety and tolerability profile indistinguishable from placebo across most parameters
.webp)
